Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib versus placebo with concurrent chemoradiotherapy for limited-stage small cell lung cancer
2025-525026-35-00Phase 3Authorised
- Sponsor
- Pharmacosmos
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Trilaciclib + concurrent chemoradiotherapy with Placebo + concurrent chemoradiotherapy (2 arms). Primary endpoints: Duration of severe neutropenia in cycle 1 and Occurrence of severe neutropenia. Planned start Oct 2026; status: authorised.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-525026-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525026-35-00.